Zostavax for the prevention of Herpes Zoster and postherpetic Neuralgia
Country | Agency | Status | Link | Details on adaptation process | Contact information |
|---|---|---|---|---|---|
Austria | LBI-HTA | Published November 2014 | Link to report
In German | The EUnetHTA assessment was translated into German; tables were directly used from the EUnetHTA assessment. National data on e.g. burden of disease/cost were added whenever available. | Dr. Ingrid Zechmeister-Koss, MA
Ingrid.Zechmeister@hta.lbg.ac.at
Anna Nachtnebel
anna.nachtnebel@hta.lbg.ac.at |
Austria | HVB | Used in direct decision-making. | Gottfried Endel
gottfried.endel@hvb.sozvers.at | ||
Belgium | RIZIV | Used in cross-checking evidence. | Francis Arickx
francis.arickx@riziv.fgov.be | ||
Croatia | AAZ | 2013 | Summary of information from the report for decision makers | Mirjana Huic (Mirjana.Huic@aaz.hr) | |
Sweden | TLV | Used in cross-checking evidence. | Johan Ponten
johan.ponten@tlv.se | ||
The Netherlands | ZIN | Published march 2014 | Link to report
In Dutch | The results of the indirect analyses in the EUnetHTA report were mentioned in the discussion section of the favourable effects. | Hedi Schelleman, Implementation Officer
hschelleman@zinl.nl |
